Biotechnology, Medical Health Aged Care 22/02/2024 10:36

The neuroscience of attending Taylor Swift’s The Eras Tour: Dr Steve Kassem available to comment

Neuroscience Research Australia < 1 mins read

< 1 mins read

Dr Steve Kassem from Neuroscience Research Australia is available to provide expert commentary on what happens to your brain during, and after, attending one of Taylor Swift's The Eras Tour concerts.

Dr Kassem is a brain cartographer and works at NeuRA's Brain Mapping Facility with Professor George Paxinos AO. He is an experienced media spokesperson, having appeared on radio and television numerous times, as well as being a regular at the Sydney Science Festival.

About us:

About NeuRA

Neuroscience Research Australia (NeuRA) is an independent, not-for-profit, medical research institute dedicated to improving the lives of people living with brain and nervous system disorders. From advances in dementia and mental health to discoveries in chronic pain and falls prevention, NeuRA has been at the forefront of neuroscience for over 30 years.

Contact details:

Contact Michelle

Senior Communications & PR Officer

0452 140 477

michelle.smith@neura.edu.au

Media

More from this category

Medical Health Aged Care, Research Development
06/09/2024
15:19

La Trobe University

Breakthrough in the hunt for broad-spectrum malaria therapy

Scientists at La Trobe University have discovered a new antibody-like molecule which could be used in therapy to prevent infection from multiple malaria parasite species. The research, recently published in Nature Communications, found that when the molecule WD34 binds with a protein produced by malaria parasites, it inhibits their ability to infect cells at different stages of the disease. Led by Professor Michael Foley, Professor Robin Anders and PhD candidate Dimuthu Angage at the La Trobe Institute for Molecular Science (LIMS), the research also showed that WD34 can protect against several different malaria parasite species. Professor Foley said the discovery…

Biotechnology
06/09/2024
12:00

Cleo Diagnostics Limited. ASX.COV

Cleo Commences U.S. Clinical Trials for its Ovarian Cancer Diagnostic Blood Test

Highlights U.S. clinical trials commenced with first patients enrolled over 8 recruitment centres Trial will validate the use ofCLEO’s ovarian cancer blood test for the U.S. market Pathway set toward FDA submission in CY2025. ___________ MELBOURNE, AUSTRALIA, 6 September 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test. Commencement of U.S. Clinical Trials CLEO’s pivotal FDA-enabling clinical trial has commenced in the United States, with first patients recruited into the study. The trial is designed to benchmarkCLEO’s technology, with…

Medical Health Aged Care
06/09/2024
10:16

Royal Australian College of GPs

NSW Government’s expanded role for pharmacy is reckless and unsafe for patients: RACGP

The New South Wales Government’s move to expand the scope of pharmacists to treat a range of conditions is politically driven and risks the health of people across the state, says the Royal Australian College of GPs. Health Minister Ryan Park made the announcement at a Pharmacy Guild conference last night that work was underway to expand pharmacists' scope to treat ear infections, wound management, nausea, gastro-oesophageal reflux disease, acne, and muscle and joint pain. RACGP NSW Chair Dr Rebekah Hoffman slammed the move as reckless and putting politics before patient safety. “This is politically driven policy, and it has…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.

Book a demo Explore our plans